SOURCE: ONE Bio, Corp.

November 22, 2011 08:00 ET

ONE Bio Releases Third Quarter 2011 Results

Third Quarter Revenue and Net Income Reached $13.5m and $1.7m, Respectively; Gross Margin Increased to 43%

AVENTURA, FL--(Marketwire - Nov 22, 2011) - ONE Bio, Corp. ("ONE" or the "Company") (OTCBB: ONBI), an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, announces unaudited results for the third quarter and year-to-date (YTD) ended September 30, 2011. Summary of financial results include the following:

Revenue for the three months ended September 30, 2011 was flat at $13,540,053, compared to $13,504,890 for the three months ended September 30, 2010, bringing revenue for the nine months ended September 30, 2011 to $38,959,672 compared to $37,347,194 for the same period last year (an increase of 4.3%). YTD the Company experienced strong revenue growth from both of its core operating business units. The Company's Chemical and Herbal Extract division ("CHE") sales increased by 26% while Company's Organic Products division ("OP") sales increased by 31%. This increase in sales was partly offset by a decrease of $6.7 million in sales in the Company's non-core third party financing business ("FIN"), which sales decrease was not as a result of loss of customers but rather a business model change which focused the division's revenues towards transaction based fees with considerably higher gross margins.

Net income for the three months ended September 30, 2011 reached $1,746,736, compared to $1,912,286 for the three months ended September 30, 2010, bringing net income for the nine months ended September 30, 2011, to $6,162,051 compared to $5,898,845 for the same period last year, an increase of 4.4%. Net income for the three months ended September 30, 2011 included a write-off of intangible assets in the CHE division of 745k, a $354K adjustment for a hedge in the FIN division and a $300k legal expense associated to the S1 withdrawn by the Company earlier this year, for a total adjustment to net income of $1.4 million.

Gross profit for the three months ended September 30, 2011 was $5,757,721 as compared to $5,020,691 for the same period in 2010. Gross margin was up at 43% compared to 37% for the third quarter of 2010. The increase in gross margin for the third quarter of 2011 was primarily due to the increased margin in the Company's newer products which were launched in the second half of 2010, and higher margin in the Company's FIN business which reached 39% versus 17% in the same quarter last year. Gross profit for the nine months ended September 30, 2011 continued its positive trend. The Company produced 45% gross margin as compared to 38% for the nine months ended September 30, 2011. The business units margin continued to stabilize with the CHE unit at 52% due to Resveritrol, Ganoderma Tea and Green Tea extracts, while the OP unit contributed 39% from strong contributors of Spring Bamboo Shoots, Seasoned Bamboo Shoots and Seasoned Vegetables while the FIN business unit contributed 42% versus 17% from the prior year. The gross margin reflects a positive trend over the past few quarters and the Company will continue to focus on improving the gross margin.

Operating income for the three months ended September 30, 2011 remained stable at $3,068,901, compared to $3,130,103 for the three months ended September 30, 2010, bringing operating income for the nine months period ended September 30, 2011 to $10,311,671 as compared to $9,586,465 for the same period a year ago. Operating expenses for the third quarter of 2011 totaled $2,688,820 as compared to $1,890,588 in the same period a year ago, bringing operating expenses for the nine months period ended September 30, 2011 to $7,291,119 as compared to $4,473,621 for the same period in 2010. The increase in operating expenses was primarily related to higher selling expenses and $1.4 million in net income adjustments as outlined above, while 2010 operating expenses were reduced by a one-time tax gain.

Earnings per share for the three months ended September 30, 2011 reached $0.23 ($0.22 on a fully diluted basis), compared to $0.31 ($0.29 on a fully diluted basis) for the three months ended September 30, 2010 bringing earnings per share for the nine months ended September 30, 2011 to $0.87 ($0.82 on a fully diluted basis) compared to $0.98 ($0.93 on a fully diluted basis) for the same period last year.

As of September 30, 2011, cash and cash equivalents totaled $14.5 million, working capital totaled $18.1 million, and shareholders' equity was $49.3 million.

Three months ended September 30, Nine months ended September 30,
2011 2010 2011 2010
Revenues $ 13,540,053 $ 13,504,890 $ 38,959,672 $ 37,347,194
Cost of sales 7,782,332 8,484,199 21,356,882 23,287,108
Gross profit 5,757,721 5,020,691 17,602,790 14,060,086
Operating expenses
General and administrative expenses 1,583,385 1,436,565 5,301,402 3,695,867
Intangible assets expense 744,502 - 744,502 -
Research and development expenses 85,011 73,248 300,338 186,856
Selling and marketing expenses 275,922 380,775 944,877 590,898
2,688,820 1,890,588 7,291,119 4,473,621
Income from operations 3,068,901 3,130,103 10,311,671 9,586,465
Interest and financing expense (422,446 ) (172,689 ) (1,141,933 ) (546,979 )
Interest income 25,402 9,316 58,812 21,935
Other expense (157,222 ) (231,871 ) (126,081 ) (592,503 )
Income before income taxes 2,514,635 2,734,859 9,102,469 8,468,918
Provision for income taxes (734,795 ) (710,510 ) (2,833,682 ) (2,214,710 )
Net income 1,779,840 2,024,349 6,268,787 6,254,208
Net income attributable to non-controlling interest (33,104 ) (112,063 ) (106,736 ) (355,363 )
Net income attributable to Company $ 1,746,736 $ 1,912,286 $ 6,162,051 $ 5,898,845
Earnings per share
-Basic $ 0.23 $ 0.31 $ 0.87 $ 0.98
-Diluted $ 0.22 $ 0.29 $ 0.82 $ 0.93
Weighted average number of shares outstanding
-Basic 7,636,568 6,158,559 7,097,667 6,007,606
-Diluted 8,113,047 6,529,259 7,537,201 6,373,265

"Our third quarter 2011 results demonstrate the continued robust demand for our products in both of our two core business units," stated Marius Silvasan, ONE's CEO. "The new products we launched during 2010 helped boost our gross margin to 45% from 38% for the nine months ended September 2011 compared to the same period a year ago. The significant increase in gross margin validates our business model and the strategy we adopted in 2010. Part of our net income gains for 2011 were off-set by $1.4 million in net income adjustments for the nine months ended September 30, 2011. Notwithstanding these adjustments, our net income for YTD 2011 ended September 30 is 4.4% higher than the same period a year ago."

About ONE Bio, Corp.
ONE Bio, Corp. ("ONE") (OTCBB: ONBI) (www.onehcorp.com), headquartered in Miami, FL, is an innovative company utilizing patented green process manufacturing to produce raw chemicals and herbal extracts, natural supplements and organic products. ONE is focused on the Asia-Pacific region and the United States. Key products include widely recognized Solanesol, CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic bamboo health food and beverages. ONE has experienced solid organic growth driven by a robust demand for its products in China, Japan and the United States.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). ONE Bio, Corp. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and ONE Bio, Corp. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Contact Information

  • Company Contact:
    Marius Silvasan
    CEO
    Tel: +888.676.4445
    Email: msilvasan@onehcorp.com

    Investor Relations Contact:
    Investor Relations & Corporate Communications
    Tel: 888-676-4445
    Email: ir@onehcorp.com